GTC Biotherapeutics to Host First Quarter 2007 Earnings Call and Webcast on Thursday, May 3, 2007.FRAMINGHAM, Mass. -- GTC GTC See: Good 'til cancelled order GTC See good-till-canceled order (GTC). Biotherapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :GTCB GTCB Gulf Tax Credit Bond (Alabama, Louisiana, Mississippi, USA) ) ("GTC") announced today that its financial results for the first quarter 2007 will be released on Thursday, May 3, 2007 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on May 3 starting at 10:00 a.m. Eastern Time. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows: Live Call - In the United States, dial 1-866-362-4820 Outside the United States, dial 1-617-597-5345 Reference call ID: when prompted 63342680 Audio Archive - In the United States, dial 1-888-286-8010 Outside the United States, dial 1-617-801-6888 Reference call ID: when prompted 75806146 NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until May 10, 2007. The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). About GTC Biotherapeutics GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal Transgenic animal Animals that have had genes from other species inserted into their genetic code. Mentioned in: Glycogen Storage Diseases technology. ATryn([R]), our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment prophylactic treatment n. The institution of measures to protect a person from a disease to which he or she has been, or may be, exposed. Also called preventive treatment. of deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn([R]) is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene transgene a gene that has been incorporated into the genome of another organism. . In addition to ATryn([R]), GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma blood plasma n. The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases. GTC has also recently been granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion